"This round of medication is on the house. The next one will be, too. But eventually, California's Gilead Sciences will start charging Americans for remdesivir, the drug that recently became the only therapeutic agent shown to cut down the recovery from COVID-19."
The Minnesota COVID-19 Ethics Collaborative (MCEC) is co-led by Debra DeBruin, PhD, Interim Director of the Center for Bioethics, and Susan M. Wolf, JD, Chair of the Consortium on Laws and Values in Health, Environment & the Life Sciences.
